Biontech Se Stock Price To Earnings To Growth
| 22UA Stock | EUR 103.00 4.60 4.28% |
BioNTech SE fundamentals help investors to digest information that contributes to BioNTech's financial success or failures. It also enables traders to predict the movement of BioNTech Stock. The fundamental analysis module provides a way to measure BioNTech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioNTech stock.
BioNTech |
BioNTech SE Company Price To Earnings To Growth Analysis
BioNTech's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Current BioNTech Price To Earnings To Growth | 0.04 X |
Most of BioNTech's fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioNTech SE is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, BioNTech SE has a Price To Earnings To Growth of 0.0445 times. This is 93.73% lower than that of the Healthcare sector and 98.58% lower than that of the Biotechnology industry. The price to earnings to growth for all Germany stocks is 99.09% higher than that of the company.
Did you try this?
Run Fundamental Analysis Now
Fundamental AnalysisView fundamental data based on most recent published financial statements |
| All Next | Launch Module |
BioNTech Fundamentals
| Return On Equity | 0.76 | |||
| Return On Asset | 0.43 | |||
| Profit Margin | 0.56 % | |||
| Operating Margin | 0.68 % | |||
| Current Valuation | 29.68 B | |||
| Shares Outstanding | 242.68 M | |||
| Shares Owned By Insiders | 64.00 % | |||
| Shares Owned By Institutions | 18.41 % | |||
| Price To Earning | 45.99 X | |||
| Price To Book | 2.31 X | |||
| Price To Sales | 2.19 X | |||
| Revenue | 18.98 B | |||
| Gross Profit | 16.07 B | |||
| EBITDA | 15.13 B | |||
| Net Income | 10.29 B | |||
| Cash And Equivalents | 914.9 M | |||
| Cash Per Share | 3.75 X | |||
| Total Debt | 171.6 M | |||
| Debt To Equity | 0.05 % | |||
| Current Ratio | 2.67 X | |||
| Book Value Per Share | 76.45 X | |||
| Cash Flow From Operations | 889.7 M | |||
| Earnings Per Share | 38.32 X | |||
| Price To Earnings To Growth | 0.04 X | |||
| Target Price | 334.89 | |||
| Number Of Employees | 4 K | |||
| Beta | 0.2 | |||
| Market Capitalization | 30.49 B | |||
| Total Asset | 15.83 B | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 15.83 B |
About BioNTech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioNTech SE's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioNTech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioNTech SE based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in BioNTech Stock
When determining whether BioNTech SE offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNTech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biontech Se Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biontech Se Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..